The TGA down-scheduling that made Australia the first country where psychiatrists can legally prescribe MDMA and psilocybin.
Australia's psychedelic rescheduling made MDMA and psilocybin legal medicines for two narrow psychiatric uses. The Therapeutic Goods Administration (TGA) made the decision in February 2023. It took effect on 1 July 2023.
The change does not legalize these drugs for everyone. It creates a tightly controlled medical pathway. A specially approved psychiatrist can prescribe MDMA for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression (TRD).
Australia was the first country to reschedule psilocybin and MDMA as medicines at the national drug-regulator level. This page covers only that TGA decision. For the broader country-by-country picture, see our guide to where MDMA is legal.
The 2023 decision turned Australia into a live test of medical psychedelics at scale. Regulators in other countries now watch how the Australian model performs in practice. The early signal is mixed: the pathway is legal, but real-world access stays small and expensive.
The decision was also a surprise. The TGA had rejected an earlier 2021 bid to reschedule both drugs, citing weak evidence. Its February 2023 reversal came after a fresh expert review and public submissions. That history matters: the pathway rests on a regulator's judgment call, not a full marketing approval, and it could be tightened if safety signals emerge.
The rescheduling covers exactly two diagnoses. MDMA is for post-traumatic stress disorder. Psilocybin is for treatment-resistant depression — meaning depression that has not improved after at least two different standard treatments.
Nothing else is included. There is no legal pathway under this decision for anxiety, addiction, end-of-life distress, or general wellbeing. A psychiatrist who wants to use these drugs for another condition would need a separate clinical-trial approval, not the Authorised Prescriber route.
The rescheduling moved MDMA and psilocybin from Schedule 9 to Schedule 8, but only for the two approved indications. Everything else about them stayed in Schedule 9. Australia's drug classes live in a document called the Poisons Standard.
The split is the key detail many summaries miss. State health rules put it plainly: MDMA "remains as a Schedule 9 substance for indications other than" PTSD, and psilocybin remains Schedule 9 for indications other than treatment-resistant depression. The drug only becomes Schedule 8 once it is labelled and dispensed for a specific authorised patient.
Only a psychiatrist with Authorised Prescriber approval can legally prescribe MDMA or psilocybin in Australia. A regular GP cannot. A regular psychiatrist cannot either, unless they hold this specific approval.
To become an authorised prescriber for these substances, a psychiatrist must:
Treatment is not a single pill. A course pairs the dosing sessions with preparation and integration psychotherapy, usually with two clinicians present during the dose. Learn the basics of each medicine in our MDMA guide and psilocybin guide.
A standard program runs over several weeks, not a single visit. The structure is what drives both the clinical results and the high cost. Most protocols follow three stages.
Patients are monitored closely during and after each dose. The setting is a clinic, not a home. This intensity of support is the main reason a single course can take dozens of clinician-hours.
The two-step approval, the training requirement, and the staffing model create a deliberate bottleneck. As of late 2025, the number of approved prescribers could still "be counted in the dozens." That scarcity is the single biggest reason a legal pathway has produced so few treated patients.
A full course of MDMA-assisted therapy in Australia has been reported at around AUD $30,000 out of pocket. A single-dose psilocybin program with preparation and integration sessions has been reported near AUD $10,000. Price tracks clinician time, not the drug itself.
Medicare and most private health insurers do not cover the therapy. So the cost falls almost entirely on the patient. This is the information that rarely survives the headlines: the law made the medicine legal, but it did not make it reachable.
The uptake numbers show how narrow the door is. By mid-September 2025, reporting put cumulative treatment at roughly 87 MDMA-for-PTSD patients and 47 psilocybin-for-depression patients — under 200 people across the whole country in more than two years. A legal world first, with patient volumes you could fit in a lecture hall.
The cost is not mainly the drug — it is the people and the time. Each dosing session needs trained clinicians on hand for hours. Add the preparation and integration sessions, and the clinician-hours stack up fast.
Few clinics can run this model, and few prescribers are approved to lead it. That scarcity keeps both prices and waiting lists high. It is the practical reason a "legal" treatment still reaches so few people — a regulatory win that has not yet become a public-health one.
Australia and US states like Oregon and Colorado all created legal psychedelic access, but through very different models. Australia uses a medical, prescription-based route. The US states use a supervised, non-prescription "service center" route. The table compares them.
| Feature | Australia (TGA, 2023) | Oregon / Colorado (US states) |
|---|---|---|
| Legal model | Medical prescription (Schedule 8) | Supervised use at licensed centers; no prescription |
| Who provides it | Authorised-prescriber psychiatrist | Trained, state-licensed facilitator (no clinical license required) |
| Diagnosis required | Yes — PTSD (MDMA) or treatment-resistant depression (psilocybin) | No diagnosis or referral needed |
| Substances | MDMA and psilocybin only | Psilocybin (Colorado can add DMT, ibogaine, mescaline) |
| Personal possession | Still illegal (Schedule 9 for non-approved use) | Decriminalized in Colorado; not statewide in Oregon |
| Typical cost | ~AUD $10,000–$30,000 per course, mostly self-funded | ~USD $1,000–$3,000+ per session, self-funded |
When Australia's model fits: if you want a medical, psychiatrist-led path tied to a specific diagnosis and you can self-fund a large bill. When the US state model fits: if you want supervised access without a diagnosis and without a prescription. For a different European medical route, compare the Czech Republic's psilocybin law.
Two years in, the Australian program is best described as a careful start, not a rollout. The legal framework works as designed, but the numbers treated stay small. Clinicians and regulators are still gathering real-world evidence.
The case for it rests on the trial data that drove the 2023 decision. Reporting on early Australian PTSD patients has pointed to meaningful relief for many. But these are early, self-funded cohorts, not a population-scale result, and long-term outcome data is still thin.
The case against rushing rests on safety and standards. Australia's psychiatry college has urged caution, stressing the need for proper training, screening, and protocols. Both sides agree on one point: the coming years of Australian data will shape how other countries decide to move.
Outside the two approved medical uses, MDMA and psilocybin are still prohibited Schedule 9 substances in Australia. The rescheduling did not legalize recreational use, possession, or supply in any way.
Still illegal across Australia:
If you are weighing a legal, supervised experience elsewhere, our find a retreat tool can help you compare options by country and legal model. Always confirm the local law first.
MDMA is legal in Australia only as a controlled (Schedule 8) medicine when prescribed by an authorised-prescriber psychiatrist for post-traumatic stress disorder. For every other use it remains a prohibited Schedule 9 substance. You cannot buy it, possess it recreationally, or get it from a regular GP.
Psilocybin is legal in Australia only as a Schedule 8 medicine when an authorised-prescriber psychiatrist prescribes it for treatment-resistant depression. For all other purposes it stays a prohibited Schedule 9 substance. Magic mushrooms picked or grown for personal use remain illegal.
The TGA announced the final decision on 3 February 2023, and the change took effect on 1 July 2023. From that date, psilocybin and MDMA moved from Schedule 9 (prohibited) to Schedule 8 (controlled) for the two approved psychiatric indications only.
A full course of MDMA-assisted therapy has been reported at around AUD $30,000 out of pocket, with single-dose psilocybin programs near AUD $10,000. Medicare and most private insurers do not cover it, so almost all patients pay the full cost themselves.
No. Only a psychiatrist approved as an Authorised Prescriber can prescribe MDMA or psilocybin. They must first get sign-off from a registered human research ethics committee, then approval from the TGA. As of late 2025 the number of approved prescribers was still only in the dozens.
Australia was the first country to reschedule psilocybin and MDMA as medicines at the national drug-regulator level, through the TGA's 2023 decision. Some other places allow access through trials or limited frameworks, but Australia's nationwide prescribing pathway was a regulatory world first.
Australia's prescription model is just one route. Compare supervised, legal options by country and check where each substance stands.
→ Find a legal retreat or clinic · Check legal status by state
Get Australia's Psychedelic Rescheduling updates
New votes, rules, court rulings, and access changes for Australia's Psychedelic Rescheduling — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.